Research programme: Parkinson's disease therapeutics - PeptimmuneAlternative Names: DEEP-PD
Latest Information Update: 29 Aug 2011
At a glance
- Originator Peptimmune
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Parkinson's disease